Acta Pharmaceutica Sinica B · 2024 · 17 citations · 58 references
Life SciencesImmunologyNutritional SciencesAgingInflammationInnate ImmunityHepatic FibrosisInflammatory SignalingLiver DiseaseMicrorna BiologyNanomedicineOral NanocarriersKupffer Cell FunctionKupffer CellsNanoparticlesNf-κb SignalingNuclear Factor Kappa B ActivationNuclear Factor Kappa B InhibitionNuclear Factor Kappa B ModulationNuclear Factor Kappa B Signaling
Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), has emerged as the leading cause of liver failure and related death. Currently, no medication is specifically approved to treat NAFLD or NASH. Here we report that oral administration of honey vesicle-like nanoparticles (H-VLNs) to naturally aged mice protects the liver from NASH development. H-VLNs are dominantly taken up by Kupffer cells in the liver and suppress hepatic chronic inflammation and further development of fibrosis and nodule formation in aged mice. Besides their reported anti-inflammasome function, H-VLNs are found to inhibit the transcriptional activities of C-JUN and nuclear factor-kappa B (NF-κB). MicroRNAs miR5119 and miR5108 and phenolic compound luteolin in H-VLNs are identified in suppressing both the C-JUN and NF-κB pathways. Collectively, oral intake of H-VLNs represents a promising new user-friendly modality to prevent the development of NASH.
58
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Daehwan Kim, Joseph M. Paggi, Chanhee Park et al. · Nature Biotechnology · 2019 · 15.7K citations · Full text
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Yingyao Zhou, Bin Zhou, Lars Pache et al. · Nature Communications · 2019 · 15.6K citations · Full text